Justice Dept. announces nearly $17 billion mortgage settlement with Bank of America Asia stocks mostly higher after Wall St record close; markets await Fed chief Yellen's speech Gap tops 2 Q profit expectations, meets revenue forecasts United Airlines is improving first class meal offerings in push to win over business travelers US Census study finds that rich got richer, poor poorer between 2000 and 2011 Home Depot says US retail head Craig Menear will become CEO; Frank Blake will remain chairman Airline industry trade group predicts Labor Day air travel will rise 2 percent over last year Family Dollar spurns Dollar General takeover bid on antitrust issues, backs Dollar Tree deal Measure of economy's future health posts 0.9 percent rise in July, biggest gain since March Housing recovery accelerates as sales of existing homes rise for a 4th straight month» Read More
*Pfizer works on next move in takeover bid for Astrazeneca. Leading the Nasdaq down was Amazon.com, which extended Friday's sharp decline a day after its earnings report.
Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.
NEW YORK, April 28- Shares of AstraZeneca surged on Monday after a takeover offer, lifting global equity markets on speculation of further corporate deal-making, while crude oil prices fell on increased U.S. sanctions against Russia over the Ukraine crisis.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
*Pfizer works on next move in takeover bid for Astrazeneca. *U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid to take over Britain's AstraZeneca Plc after having two bids rejected.
STOCKHOLM, April 28- Swedish drugmaker Meda has rejected an improved takeover offer from U.S. generics firm Mylan, saying it was confident in its future as an independent company and its biggest shareholder did not support the bid.
PARIS/ NEW YORK, April 24- Alstom said on Thursday it was not informed of any potential public tender offer for its shares, which opened 17 percent higher after Bloomberg reported that General Electric was in talks to buy the French turbine and train maker for about $13 billion.
CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.
Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.
The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.